Brief: Fusen Pharmaceutical Company Sees A Decline Of Over 40% In HY Profit Attributable
03/07/2019 10:11
July 3 (Reuters) - Fusen Pharmaceutical Company Ltd
1652.HK :
* EXPECTED TO RECORD A DECLINE BY MORE THAN 40% IN PROFIT
ATTRIBUTABLE FOR SIX MONTHS
Source text for Eikon: ID:nHKS5Fgkl2
Further company coverage: 1652.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Fusen Pharmaceutical
See all newsBrief: Fusen Pharmaceutical Logs HY Loss Attributable RMB13.6 Million
Brief: Fusen Pharmaceutical Says Doxazosin Mesylate Extended-Release Tablets Approved For Marketing In China
Brief: Fusen Pharmaceutical Says Peramivir Injection First Neuraminidase Inhibitor Approved In China For Intravenous Influenza Treatment
Brief: Fusen Pharmaceutical Says Investors To Contribute RMB300 Mln For 34% Stake Subscription Of Henan Fusen Pharmaceutical
Brief: Fusen Pharmaceutical Says Piracetam Injection Approved For Marketing By NMPA